Clinical Trial Details

A Phase II randomized trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy (Tapimmune FRV-004)

This is a double-blind, randomized, parallel groups Phase II trial. Patients with platinum-sensitive advanced ovarian cancer, defined as a lack of progression by RECIST v1.1 criteria following completion of standard-of-care chemotherapy, including a minimum of 4 cycles of a platinum-containing regimen. Patients will be randomized to either the vaccine regimen with GM-CSF adjuvant or GM-CSF adjuvant alone as a control group. Treatment will be administered as a consolidation therapy within one year of the last administration of platinum, targeting the first remission.

Learn More

Principal Investigator(s)


Tapimmune, Inc.


Maureen Magnani


Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.